Eden Radioisotopes scores funding for isotope reactor production

Huge Two-Day Clean Sweep Auction July 24-25th. Click Here to Bid!

Endroit courant :
> This Story

Ouverture ou Registre to rate this News Story
Forward Printable StoryPrint Comment




Molecular Imaging Homepage

Bracco Imaging to acquire Blue Earth Diagnostics for $450 million Will gain rights over Axumin

MiE showcases cardiac PET scanner, Ancoris, at SNMMI Provides simultaneous 3D cardiac PET perfusion and CFR

First dual PET isotope scans performed on living organism Discussed at SNMMI 2019 Annual Meeting

Siemens showcases works in progress at SNMMI Includes TeamPlay, syngo Virtual Cockpit and a number of AI algorithms

Philips shares insights on PET/CT utilization trends at SNMMI Continued growth in use expected through 2019

Software innovations for patient-specific theranostics and molecular radiotherapy Trends that will impact the future of medicine

GE debuts Discovery IQ Gen 2 PET/CT system at SNMMI Equipped with MotionFree to prevent blurring of images

Rethinking training and education for the future of medicine at SNMMI Discussing innovations and efforts of SNMMI Technologist Section

Theranostics continue to gain momentum Investments ramp up but challenges remain

SNMMI Product Showcase Don't miss these solutions on the exhibit floor

Eden Radioisotopes is constructing a
reactor that will primarily produce

Eden Radioisotopes scores funding for isotope reactor production

par John R. Fischer , Staff Reporter
Startup Eden Radioisotopes has established an investment agreement with Yates Family company Abo Empire that will help fund the construction of a reactor for the production of medical isotopes.

The New Mexico-based nuclear structure will be less than 2 MW and used primarily to generate Molybdenum-99, the parent isotope of Technetium-99m. Its construction is expected to help curb the impact of supply shortages of the highly desirable radioisotope for molecular imaging.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED

“The Eden approach uses a historically well understood reactor and low-enriched uranium Mo-99 target science that has been validated to produce commercial quantities of Mo-99,” Chris Wagner, COO of Eden Radioisotopes, told HCB News. “The Eden reactor uses an all-target core that would operate 22 hours, seven days a week. This allows for Molybdenum-99 targets to be continuously irradiated and readily available for processing as needed. Other typical current medical isotope reactors may operate on a cycle of some period of time, such as 28 days, and then be down for a week of routine maintenance. During times of market shortage(s), this operational difference would allow Eden to quickly ramp up mo-99 production to fill a shortfall.”

A $4 billion-a-year global market, 40 million diagnostic molecular imaging procedures take place each year worldwide, with 80 percent requiring Technetium-99m. Of that amount, 90 percent are either cardiac or cancer-related.

Distribution of Mo-99, however, is a challenge, due to its short half-life, which prevents it from being stockpiled. In addition, only five reactors in Canada, Netherlands, South Africa, Belgium and Australia are primary producers of the isotope and often encounter numerous unplanned outages for repairs, due to their ages. This leads to supply shortages and hikes in the cost, scenarios which may become more frequent, with the Canadian reactor now offline and the 60-year-old Dutch one predicted to be at the end of its lifespan.

To keep demand stable, Eden plans to utilize exclusively licensed, patented reactor technology from Sandia National Laboratories to generate Mo-99 in large quantities. The reactor will utilize an all-target, variable-sized core of low-enriched uranium, which only requires downtime measured in hours instead of days, with the entire core of Mo-99 targets able to be processed to produce more than 10,000 Curies of Mo-99 per week.

Its size, which is similar to that of research reactors on many university campuses across the U.S., also helps reduce the costs for fuel, downtime, maintenance, personnel and large-scale operations that make large reactors, which range from 10 MW to 200 MW, not cost-effective.
  Pages: 1 - 2 >>

Molecular Imaging Homepage

You Must Be Logged In To Post A Comment